Collagen synthesis and ECM remodeling pathways (null)

Collagen synthesis and ECM remodeling pathways are sets of highly regulated biological processes responsible for producing, modifying, and degrading the extracellular matrix, predominantly collagen, in tissues. **Collagen synthesis** involves ribosomal production of procollagen, post-translational modifications such as proline and lysine hydroxylation, secretion, and extracellular assembly into fibrils[4]. **ECM remodeling** is mediated by a dynamic interplay between matrix-degrading enzymes (e.g., MMPs), their inhibitors (TIMPs), and cell-generated contractile forces that restructure ECM architecture[1][2][3]. These pathways are fundamental to tissue development, repair, and homeostasis; dysregulation contributes to fibrosis, cancer progression, impaired wound healing, and inflammatory conditions[2][3][4]. They are not a single targetable molecule, but rather encompass a wide range of molecules with distinct yet interrelated functions. For therapeutic, research, or structured database purposes, you should refer to **specific enzymes, signaling molecules, or receptors within these pathways** (e.g., collagen type I alpha 1 chain, matrix metalloproteinase-9, lysyl oxidase, transforming growth factor beta receptor, etc.) rather than the broad pathway terminology.

Other names

Collagen biosynthesis pathwayECM remodeling pathwayExtracellular matrix synthesis and degradationMatrix turnover

Inhibition of collagen synthesis (e.g., by blocking TGF-β or related signaling) Inhibition of ECM protein crosslinking (e.g., lysyl oxidase inhibition) Increased ECM degradation (e.g., collagenase, MMP activators) Inhibition of ECM-degrading enzymes (e.g., MMP inhibitors)